Diazepam Rektiole Allgen (Diazepam)

Diazepam Rektiole Allgen rectal suppository is indicated for several acute clinical situations where rapid systemic delivery of a benzodiazepine is required.

• Acute seizure control, including status epilepticus, when intravenous access is unavailable or delayed.
• Adjunctive therapy for muscle spasm associated with neurological disorders.
• Short‑term relief of severe anxiety when oral administration is not feasible.
• Sedation prior to diagnostic or therapeutic procedures.
• Management of breakthrough seizures in patients already on chronic oral diazepam therapy.

The pharmacologic profile of diazepam can produce a range of adverse effects, most of which are dose‑dependent and reversible after discontinuation.

Common

• Drowsiness or sedation.
• Fatigue and weakness.
• Impaired coordination or ataxia.
• Cognitive slowing or memory difficulty.
• Nausea or mild gastrointestinal upset.

Serious

• Respiratory depression, especially with concurrent depressants.
• Severe hypotension or cardiovascular collapse.
• Paradoxical reactions such as agitation, aggression, or seizures.
• Hepatic enzyme elevation or liver injury.
• Dependence, tolerance, and withdrawal symptoms with prolonged use.

Because diazepam affects the central nervous system, clinicians should evaluate patient-specific factors and monitor for safety concerns before and during therapy with the rectal formulation.

• Assess respiratory function in patients with COPD, asthma, or sleep apnea.
• Use caution in individuals with a history of substance use disorder or dependence.
• Avoid use during the first trimester of pregnancy; it is classified as Category D.
• Adjust dose in elderly patients due to increased sensitivity and slower metabolism.
• Monitor liver function tests in patients with hepatic impairment.
• Counsel patients about the risk of impaired driving or operating machinery.
• Discontinue gradually to reduce withdrawal risk after prolonged therapy.

Diazepam is metabolized primarily by hepatic CYP enzymes and can interact with many other medications; understanding these interactions helps prevent adverse outcomes.

Avoid

• Concomitant use with other central nervous system depressants (e.g., opioids, barbiturates, alcohol) due to additive respiratory depression.
• Strong CYP3A4 inducers such as rifampin, carbamazepine, or phenytoin, which may reduce diazepam plasma levels.
• Potent CYP3A4 inhibitors like ketoconazole or clarithromycin, which can increase diazepam concentrations and toxicity.
• Antifungal agents (e.g., itraconazole) that inhibit metabolism and raise systemic exposure.

Use with caution

• Antidepressants, especially SSRIs or MAO inhibitors, which may enhance sedation.
• Antihistamines and antihypertensives that can increase drowsiness.
• Other benzodiazepines or sedative hypnotics, requiring dose adjustments.
• Herbal supplements such as St. John’s wort that may alter enzyme activity.